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Abstract
Slowly inactivating Na+ channels conducting “late”Na+ current (INa,late) contribute to ventricu-
lar arrhythmogenesis under pathological conditions. INa,late was also reported to play a role in
chronic atrial fibrillation (AF). The objective of this study was to investigate INa,late in human
right atrial cardiomyocytes as a putative drug target for treatment of AF. To activate Na+ chan-
nels, cardiomyocytes from transgenic mice which exhibit INa,late (ΔKPQ), and right atrial cardi-
omyocytes from patients in sinus rhythm (SR) and AF were voltage clamped at room
temperature by 250-ms long test pulses to -30 mV from a holding potential of -80 mVwith a
100-ms pre-pulse to -110mV (protocol I). INa,late at -30 mVwas not discernible as deviation
from the extrapolated straight line IV-curve between -110 mV and -80 mV in human atrial
cells. Therefore, tetrodotoxin (TTX, 10 μM) was used to define persistent inward current after
250 ms at -30 mV as INa,late. TTX-sensitive current was 0.27±0.06 pA/pF in ventricular cardio-
myocytes from ΔKPQmice, and amounted to 0.04±0.01 pA/pF and 0.09±0.02 pA/pF in SR
and AF human atrial cardiomyocytes, respectively. With protocol II (holding potential -120
mV, pre-pulse to -80 mV) TTX-sensitive INa,late was always larger than with protocol I. Ranola-
zine (30 μM) reduced INa,late by 0.02±0.02 pA/pF in SR and 0.09±0.02 pA/pF in AF cells. At
physiological temperature (37°C), however, INa,late became insignificant. Plateau phase and
upstroke velocity of action potentials (APs) recorded with sharp microelectrodes in intact
human trabeculae were more sensitive to ranolazine in AF than in SR preparations. Sodium
channel subunits expression measured with qPCRwas high for SCN5A with no difference
between SR and AF. Expression of SCN8A and SCN10A was low in general, and lower in AF
than in SR. In conclusion, We confirm for the first time a TTX-sensitive current (INa,late) in right
atrial cardiomyocytes from SR and AF patients at room temperature, but not at physiological
temperature. While our study provides evidence for the presence of INa,late in human atria,
the potential of such current as a target for the treatment of AF remains to be demonstrated.
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Introduction
The long-lasting plateau phase of the cardiac action potential is supported by L-type Ca2+ cur-
rent [1], but slowly inactivating Na+ channels conducting “late” Na+ current (INa,late) also con-
tribute to the plateau phase and are related to ventricular arrhythmogenesis under pathological
conditions [2–4]. Single channel studies have revealed that INa,late is conducted by cardiac
Nav1.5 channels operating in special gating modes ([4]; for review see [5]) that clearly distin-
guish them from background Na+ currents.
In animal and human ventricular cells, INa,late is enhanced in heart failure [2–4], ischemia [6]
or congenital disease (long QT syndrome 3, LQT3)[7]. In a mouse model of LQT3 (ΔKPQ), the
increase in late Na+ current results in the prolongation of action potential (AP) duration in both
ventricular and atrial tissues [8,9], suggesting that, in addition to its role in the ventricle, INa,late
can also modulate atrial repolarization. In this context it is notable that LQT3 syndrome has
been associated with familial atrial fibrillation (AF) [10–12], and a large proportion of SCN5A
mutations found in young patients with lone AF actually increased INa,late [13]. A recent study
reported the presence in human right atrial myocytes of late Na+ currents with larger amplitude
in cells from patients with chronic AF [14]. This finding is of clinical interest, because enhance-
ment of INa,late in AF could indeed contribute to the maintenance of the arrhythmia via increased
Na+ influx during the AP plateau phase leading to Ca2+ overload via modulation of NCX activity
[15,16]. Moreover, conventional antiarrhythmic drugs that block peak Na+ current (INa,peak) are
associated with considerable cardiac and extra-cardiac side effects including life-threatening
arrhythmia. Therefore, INa,late might provide a useful novel target for treatment of AF if com-
pounds that preferentially block INa,late over INa,peak can be developed. The anti-anginal drug
ranolazine seems to provide this property, since it blocks INa,late with ~40-fold higher potency
than INa,peak (i.e. IC50 values 5.9 μM for late [17] versus 244 μM for peak INa in ventricular cardi-
omyocytes [18]). Interestingly, experimental and clinical studies have shown that ranolazine has
antiarrhythmic effects in both ventricles and atria (reviewed in [19]).
In previous preliminary experiments from our laboratory [20], using a repolarizing ramp
pulse we detected INa,late only in the presence but not in the absence of the sea anemone toxin
ATXII, known to delay inactivation of INa [21]. In addition, we also did not measure any INa,late
at -30 mV as current amplitude deviating from the extrapolated straight line of background
(“leak”) current-voltage relationship between -110 mV and -80 mV [20]. Therefore we vali-
dated our step voltage clamp protocols for the detection of INa,late in cardiomyocytes from
ΔKPQmice (LQT3). These mice have a knock-in gain of function mutation in SCN5A, the
gene coding for the major cardiac sodium channel Nav1.5, which leads to increased INa,late in
both ventricular and atrial myocytes [8,22]. We then searched for the presence of INa,late as
TTX-sensitive current in atrial myocytes from patients in sinus rhythm (SR) and with chronic
AF, and studied the impact of the putative preferential INa,late blocker ranolazine on the shape
of right atrial APs. Some of the results have been published in preliminary form [23].
Materials and Methods
Human tissue samples and patient’s characteristics
The study conforms with the Declaration of Helsinki and was approved by the ethics commit-
tee of Dresden University of Technology (No. EK790799). Each patient gave written, informed
consent. Right atrial appendages were obtained from patients with SR and with chronic AF
(AF> 6 months). More information on patients is given in Table 1.
Late Sodium Currents and Ranolazine in Human AF
PLOSONE | DOI:10.1371/journal.pone.0131432 June 29, 2015 2 / 19
ΔKPQ-SCN5Amice
Animal care and experimental protocols were conducted in accordance with the German fed-
eral animal protection law and approved by the institutional committee at the Technical Uni-
versity Dresden. The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996). Experiments and analysis performed in adult littermate wild-type (WT) and het-
erozygous ΔKPQmice [9], 17–19 weeks old, were blinded to genotype (group A and B). Upon
unblinding at the end of the analysis, group A turned out to be ΔKPQ, and group B was WT.
Electrophysiological recordings
Mice were sacrificed by cervical dislocation under CO2 anesthesia. Mouse and human cardio-
myocytes were isolated as previously described [24,25]. The conventional voltage-clamp tech-
nique in the ruptured patch configuration was used to measure ion currents. Experiments were
performed at room temperature, unless otherwise stated, in the following bath solution (mM):
NaCl 120, HEPES 10, MgCl2 1, CsCl 10, glucose 10 and CaCl2 0.5 (pH 7.4, adjusted with CsOH).
Table 1. Clinical characteristics of patients
SR AF
n = 23 n = 17
General demographics
Gender [m/f] 19/4 12/5
Age [years] 64.4 ± 1.8 71.9 ± 1,6**
BMI [kg/m2] 29.8 ± 1.0 26.9 ± 1.0
Hypertension, n 20 (87.0) 17 (100.0)
Diabetes mellitus, n 8 (34.8) 8 (47.1)
Hyperlipidaemia, n 15 (65.2) 12 (70.1)
CAD, n 19 (82.6) 0
AVD/MVD, n 4 (17.4) 12 (70.1)
CAD + AVD/MVD, n 0 5 (29.4)
Hemodynamic parameters
LVEF [%] 50.6 ± 3.0 48.2 ± 4.0
LA [mm] 41.5 ± 1.7 49.6 ± 2.3**
LVEDD [mm] 51.2 ± 2.5 55.7 ± 1,9
LVWTED [mm] 12.2 ± 0.6 11.9 ± 0.4
Cardiovascular medication (n)
Digitalis (%) 0 7 (41.2)
ACE inhibitors (%) 14 (60.9) 11 (64.7)
AT1 blockers (%) 6 (26.1) 0
β-blockers (%) 20 (87.0) 15 (88.2)
Calcium channel blockers (%) 5 (21.7) 4 (23.5)
Diuretics (%) 7 (30.4) 13 (76.5)
Nitrates (%) 0 0
Lipid-lowering drugs (%) 16 (70.0) 9 (52.9)
Abbreviations: ACE, angiotensin converting enzyme; AT, angiotensin receptor; AVD, aortic valve disease; BMI, body mass index; CAD, coronary artery
disease; LA, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVWTED, left ventricular wall
thickness at end of diastole; MVD, mitral valve disease; n, number of patients
* p<0.05 Student’s unpaired t-test for continuous variables and [χ]2 test for categorical variables.
doi:10.1371/journal.pone.0131432.t001
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The pipette solution (pH 7.2, adjusted with CsOH) consisted of (mM): NaCl 5, caesiummetha-
nesulfonate 90, CsCl 20, HEPES 10, Mg-ATP 4, Tris-GTP 0.4, EGTA 10 and CaCl2 3, with cal-
culated free Ca2+ concentration of 60 nM (computer program EQCAL, Biosoft, Cambridge,
UK). Experiments were done in the presence of 1μMnisoldipine to block L-type Ca2+ currents.
After forming a giga-ohm seal and breaking into the cell, capacitance was measured with small
hyperpolarizing clamp steps from -40 mV to -42 mV. Mean values were 70.4±3.3 pF (53/23,
cells/patients) in SR and 84.5±4.4 pF (54/17) in AF myocytes (P<0.012, unpaired, two-tailed t-
test). Mean cell capacitances for murine ventricular cardiomyocytes were 101 ± 7.1 pF (15/3) in
WT and 96.7 ± 4.6 pF (33/5, difference n.s.) in ΔKPQmice. The respective capacitances for atrial
cardiomyocytes were 35.3 ± 2.8 pF (9/3) and 40.4 ± 4.1 pF (8/3; n.s.).
Voltage protocols
In protocol I [20] the cells were held close to the physiological resting membrane potential at
-80 mV, a 100 ms-long step to -110 mV was used to increase availability of Na+ channels, and
Na+ channels were activated at –30 mV (Fig 1A), giving rise to a huge peak inward current
(off-scale in Fig 1B), the major fraction of which rapidly inactivated within ~10 ms and then
declined very slowly until the end of the 250-ms pulse at -30 mV. Full activation of INa,peak at
normal Na+ concentration is likely to cause escape of voltage control due to the limitations of
the patch-clamp amplifier. In order to reduce this problem we used in protocol II a short (5
ms) activating step to +50 mV (close to the reversal potential of INa,peak to avoid loss of voltage
control) before stepping to –30 mV to observe late Na+ current, as suggested by Sossalla et al.
[14]. The cells were held at -120 mV for near complete Na+ channel availability, and for com-
parison with protocol I a 100-ms step to -80 mV between Vh and activating step was interpo-
lated in the majority of cells. When possible, both protocols were applied to the same cell
successively, and late Na+ currents were measured 50 ms and 250 ms after Na+ channels activa-
tion at -30 mV. Current amplitude was also measured at -110 and -80 mV, and at -120 and -80
mV, respectively, for quality control over time: if the difference in current amplitude after drug
application was larger than 10 pA at -80 mV (or>20 pA at -120 mV for cells without a step to
-80 mV), the experiment was excluded from statistical analysis.
Action potential recordings
Action potentials (APs) were recorded with standard intracellular microelectrodes in human
right atrial trabeculae paced at a frequency of 1 Hz [26]. The bath solution contained (in mM):
NaCl 127, KCl 4.5, MgCl2 1.5, CaCl2 1.8, glucose 10, NaHCO3 22, NaH2PO4 0.42, equilibrated
with O2-CO2 [95%:5%] at 36.5 ± 0.5°C, pH 7.4. Preparations were regularly stimulated at 1 Hz
for at least 1 hour before data acquisition with a custom-made computer program (University
of Szeged, Hungary) that also generated electrical stimuli. The following AP parameters were
analysed using the LabChart software (ADInstruments, Spechbach, Germany): resting mem-
brane potential (RMP), action potential amplitude (APA) and duration at 20%, 50% and 90%
of repolarization (APD20, APD50 and APD90), plateau potential defined as the mean potential
(mV) in the time window between 20% of APD90 plus 5 ms (PLT20), and maximum upstroke
velocity (dV/dtmax).
Expression of sodium channel subunits
Quantification of mRNA transcripts encoding for sodium channel subunits was performed on
right atrial appendage from 10 SR (mean age 75.5±1.3 years, 4 females) and 14 AF (mean age
77.2±1.1 years, 7 females) patients. Total RNA extraction, cDNA synthesis and quantitative
real-time PCR (qPCR) was performed as previously described [27]. The following pre-designed
Late Sodium Currents and Ranolazine in Human AF
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gene expression assays from Applied Biosystems were used for quantification; SCN1A
(Hs00374696_m1), SCN2A (Hs00221379_m1), SCN3A (Hs00366902_m1), SCN4A
(Hs01109480_m1), SCN5A (Hs00165693_m1), SCN8A (Hs00274075_m1), SCN10A
(Hs01045137_m1), SCN1B (Hs00962350_m1). The primers and probes targeting SCN2B,
SCN3B, and SCN4B were custom designed and synthesized by Applied Biosystems, following
submission of intron spanning sequences using Primer Express 3.0 software. PPIA (Assay
Hs99999904_m1) was used for normalization.
Chemicals and Drugs
Tetrodotoxin was purchased from Carl Roth (Karlsruhe, Germany). All other compounds were
from Sigma-Aldrich (Steinheim, Germany).
Fig 1. Effects of tetrodotoxin on INa,late in ventricular and atrial cardiomyocytes (CM) fromΔKPQ-SCN5Amice. A andB: Voltage clamp protocol Ⅰ and
examples of original current tracings recorded in ΔKPQmouse myocytes under control conditions or in the presence of 10 μM tetrodotoxin (TTX). Late
sodium currents were measured at the end of the 250 ms-long pulse at -30 mV (black arrow). As internal control, current amplitude was also measured at -80
mV and -110 mV (white arrows). C: Current densities were plotted for each voltage without (control, black circles) and after addition of 10 μMTTX (open
squares).D: Currents measured at -30 mV before (black columns) and after TTX exposure (grey columns) in myocytes from wild type (WT) and ΔKPQmice.
Numbers below the columns (x/y) indicate number of cells per number of animals. TTX-sensitive current expressed as current density (in pA/pF). **P < 0.01;
***P < 0.001; paired Student’s t-test.
doi:10.1371/journal.pone.0131432.g001
Late Sodium Currents and Ranolazine in Human AF
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Statistical analysis
Data are expressed as means ± SEM. Differences between data were compared by paired or
unpaired Student’s t test (with Welch’s correction if indicated). P<0.05 was considered statisti-
cally significant.
Results
Effects of tetrodotoxin on INa,late in cardiomyocytes from ΔKPQmice
In order to test whether the clamp protocol for testing persisting membrane current at -30 mV
as deviation from the extrapolated straight line between -110 mV (-120 mV) and -80 mV is
sensitive enough for detecting INa,late, we studied cardiomyocytes from ΔKPQmice in which
INa,late has been detected previously [8,22]. In addition we also used a slightly modified protocol
with which INa,late has been studied in human atrial cardiomyocytes [14] and applied tetrodo-
toxin (TTX, 10 μM) to test for contribution of Na+ channels. Fig 1 shows currents measured in
ventricular and atrial cells from ΔKPQ mice (Fig 1B–1D) and also from wild type (WT) mice
(Fig 1D) with protocol I. At -110 mV and at -80 mV, current amplitudes were stable in the
presence of TTX. At -30 mV control currents were outwardly directed in ventricular myocytes,
possibly due to residual IK1, whereas in atrial cells they were inwardly directed due to smaller
IK1/Ileak ratio. At -30 mV, TTX clearly unmasked a small, slowly decaying inward current. Cur-
rent amplitude 250 ms after Na+ channel activation was indeed significantly more outward in
ventricular cells and significantly less inward in atrial cells upon application of 10 μMTTX,
consistent with block of an inward current, which is conducted via Na+ channels and probably
represents INa,late. Please note, that after addition of TTX, current amplitudes at -30 mV no lon-
ger deviated from a straight line, clearly indicating the presence of a linear conductance or
background current (Fig 1C). In contrast, no effect of TTX was observed in cells fromWT
mice (Fig 1D). The amplitudes of TTX-sensitive current density determined as difference cur-
rent measured with each protocol (Fig 1D) were 0.27 ± 0.06 pA/pF in ventricular cells (n = 18
cells from 5 ΔKPQ animals; 18/5) with protocol I, and 0.63 ± 0.10 pA/pF (n = 15/4; p<0.05)
when protocol II was used (see S1 Fig), the difference being most likely due to the more nega-
tive holding potential and the subsequently larger fraction of Na+ channels available for activa-
tion with protocol II.
Although TTX significantly reduced late Na+ currents (INa,late) also in atrial cardiomyocytes
from ΔKPQ but not WT mice, the difference in TTX-sensitive current between WT and ΔKPQ
atrial cells failed to reach the level of statistical significance with either protocol (S6 Fig), proba-
bly due to the small sample size. Nevertheless, with protocol II TTX-sensitive current ampli-
tudes in ΔKPQ atrial cells were significantly larger than with protocol I, i.e. 0.50 ± 0.12 pA/pF
(n = 4/3) with protocol II, and 0.18 ± 0.05 pA/pF (n = 5/2; p = 0.030) with protocol I.
Effects of tetrodotoxin on INa,late in human atrial myocytes
As both protocols allowed the detection of late Na+ currents in ΔKPQ cardiomyocytes, we per-
formed similar experiments in human atrial myocytes from patients in sinus rhythm (SR) or
chronic atrial fibrillation (AF). Currents were analysed at room temperature 50 ms and 250 ms
(Fig 2) after Na+ channel activation. Examples of complete current tracings are given in S2 Fig As
for the murine cardiomyocyte experiments, stability of current amplitude at -80 mV (or -120 mV,
see section 2.5) was used as quality control, and recordings with a shift>10 pA at -80 mV (or
>20 pA at -120 mV) after addition of TTX were discarded. In cells from one patient in SR, we
measured a surprisingly robust late Na+ current with both protocols. This particular patient had a
Late Sodium Currents and Ranolazine in Human AF
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prolonged QTc interval preoperatively (unpublished data) and was therefore excluded from fur-
ther analysis.
At room temperature, TTX clearly decreased mean current amplitude after 250 ms at -30
mV in SR and AF cardiomyocytes (Fig 2A–2C). The amplitude of TTX-sensitive INa,late mea-
sured in AF cells was significantly larger than in SR cells (Fig 2D): 0.09 ± 0.02 pA/pF in AF
(n = 18/8) vs 0.04 ± 0.01 pA/pF in SR (n = 14/7, P = 0.021) with protocol I; and 0.18 ± 0.04 pA/
pF in AF (n = 11/7) vs 0.07 ± 0.03 pA/pF in SR (n = 12/6, P = 0.013) with protocol II (see S3
Fig). These differences were even more prominent when currents were analysed earlier in the
clamp step, i.e. after 50 ms (Fig 2, S3 Fig).
We performed additional experiments at 37°C to test whether INa,late amplitude was
increased at physiological temperature (Fig 3). Only protocol I could be used because with a
holding potential of -120 mV, recordings were too unstable for analysis. TTX significantly
Fig 2. Effects of tetrodotoxin on INa,late in human atrial myocytes from patients in sinus rhythm (SR, black) and atrial fibrillation (AF, red) 50 ms and
250ms after Na+ channel activation. A Examples of original current tracings (top) measured at room temperature with protocol Ⅰ, under control conditions
and in the presence of 10 μM TTX. Late sodium currents were measured 50 ms (left side) 250 ms (right side) after the beginning of the pulse at -30 mV (black
arrow). B: Current density plotted for each voltage yielded a straight line after addition of TTX. C: Effect of 10 μM TTX on currents expressed as current
density (in pA/pF) at -30 mV in SR and AF cardiomyocytes, and *P < 0.05, ***P < 0.001; paired Student’s t-test (B, C) for currents before and after exposure
to TTX, or unpaired Student‘s t test with Welch’s correction for TTX-sensitive current in SR and AF.
doi:10.1371/journal.pone.0131432.g002
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reduced current at -30 mV after 50 ms in AF but not in SR cells (S3A and S3C Fig). TTX-sensi-
tive currents after 50 ms were 0.08 ± 0.04 pA/pF in SR (n = 12/7) and 0.21 ± 0.05 pA/pF in AF
(n = 6/3), the difference between SR and AF just failing to reach the level of statistical signifi-
cance (P = 0.079). After 250 ms no significant TTX effects were detected (S3B and S3D Fig)
neither in SR nor AF, most likely due to a faster inactivation of the Na+ channels at physiologi-
cal temperature.
Effects of ranolazine on INa,late in human atrial myocytes
The effect of ranolazine (30 μM) on INa,late was studied at room temperature (Fig 4). Only pro-
tocol I was used in those experiments, and we found that ranolazine significantly reduced cur-
rent amplitude only in AF myocytes (Fig 4B and 4C). The amplitude of ranolazine-sensitive
late Na+ current density after 50 ms was larger in AF than in SR cells, i.e. 0.15 ± 0.02 pA/pF
(n = 12/3) and 0.04 ± 0.03 pA/pF (n = 13/5; P<0.05), respectively. After 250 ms, INa,late ampli-
tude measured as ranolazine-sensitive current density was smaller in both SR and AF (Fig 4C),
but still significantly larger in AF (0.09 ± 0.02 pA/pF) than SR cells (0.02 ± 0.02 pA/pF;
P<0.05). The AF values were similar to TTX-sensitive currents described in section 3.1.
Effects of ranolazine on human right atrial action potentials
In order to estimate the functional importance of INa,late for atrial action potentials (APs) right
atrial trabeculae from patients in SR and AF were studied in the presence of cumulatively
Fig 3. Effects of tetrodotoxin on INa,late measured at physiological temperature (37°C) with protocol I in human atrial myocytes 50ms (A, C) and 250
ms (B, D) after Na+ channel activation. Similar lay-out as in Fig 2, but without I/V curves.
doi:10.1371/journal.pone.0131432.g003
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increasing concentrations of ranolazine (3–100 μM, 20 min at each concentration). The drug
effects on all AP parameters are summarised in Tables 2 and 3. In the high concentration
range, ranolazine reduced the plateau potential (PLT20) and depressed upstroke velocity dV/
dtmax when compared to the pre-drug control values, and these effects were more prominent,
and occurred at lower concentrations, in AF than SR trabeculae (see Tables 2 and 3). In AF but
Fig 4. Effects of ranolazine on INa,late measured with protocol I in human atrial myocytes at room temperature. Similar lay-out as in Fig 3.
doi:10.1371/journal.pone.0131432.g004
Table 2. Effects of ranolazine on human right atrial action potential parameters (1 Hz) from patients in sinus rhythm (SR), n = 6.
AP parameter Ranolazine
Pre-drug control 3 μM 10 μM 30 μM 100 μM
APD90 (ms) 265.8 ± 23.0 253.4 ± 26.1 261.7 ± 27.1 237.2 ± 31.4 255.5 ± 34.0
APD50 (ms) 128.8 ± 18.8 112.0 ± 22.7 110.5 ± 22.2 55.4 ± 20.7* 88.7 ± 26.4
APD20 (ms) 5.4 ± 0.8 4.6 ± 0.5 4.8 ± 0.6 5.3 ± 1.0 14.4 ± 6.5
PLT20 mV -19.3 ± 1.3 -20.2 ± 1.7 -20.8 ± 2.1 -27.6 ± 2.1* -33.8 ± 5.1*
APA (mV) 91.5 ± 1.8 94.6 ± 3.1 92.3 ± 3.0 88.6 ± 2.9 66.0 ± 11.2
RMP (mV) -73.5 ± 1.0 -73.6 ± 0.8 -73.3 ± 1.0 -72.8 ± 0.8 -70.2 ± 1.1
dV/dtmax (V/s) 238.7 ± 12.8 274.6 ± 30.0 251.8 ± 32.6 221.0 ± 31.4 126.2 ± 26.9**
*P<0.05,
** P<0.01;
***P<0.001, versus pre-drug control
doi:10.1371/journal.pone.0131432.t002
Late Sodium Currents and Ranolazine in Human AF
PLOSONE | DOI:10.1371/journal.pone.0131432 June 29, 2015 9 / 19
not in SR trabeculae, ranolazine prolonged APD90 at all concentrations and reduced APA at or
>10 μM. The stability of AP parameters over time was studied in the absence of any drug
(time-matched controls, TMC). PLT20 and dV/dtmax tended to decrease, and APD90 remained
constant over time (Fig 5). Compared with TMC, 30 μM ranolazine significantly reduced
Table 3. Effects of ranolazine on human right atrial action potential parameters (1 Hz) from patients in atrial fibrillation (AF), n = 7.
AP parameter Ranolazine
Pre-drug control 3 μM 10 μM 30 μM 100 μM
APD90 (ms) 214.3 ± 13.5 221.3 ± 13.4*** 233.7 ± 14.9*** 250.3 ± 16.7** 267.9 ± 22.0*
APD50 (ms) 97.9 ± 7.7 97.3 ± 7.9 97.9 ± 8.9. 94.0 ± 8.5 102.7 ± 14.5
APD20 (ms) 23.1 ± 2.9 22.1 ± 2.6 21.9 ± 2.4 20.9 ± 2.6 25.0 ± 3.0
PLT20 mV -7.4 ± 2.6 -9.3 ± 3.1* -12.2 ± 3.3*** -17.2 ± 3.1*** -23.6 ± 3.9***
APA (mV) 103.3 ± 1.1 103,3 ± 1.2 100.5 ± 1.5* 94.9 ± 2.1* 80.7 ± 7.0*
RMP (mV) -79.0 ± 0.7 -78.4 ± 0.5 -78.1 ± 0.6 -77.9 ± 1.1 -76.1 ± 1.8
dV/dtmax (V/s) 233.4 ± 19.3 225.7 ± 24.1 197.1 ± 24.5** 188.1 ± 17.5* 114.7 ± 25.0***
*P<0.05,
** P<0.01;
***P<0.001, versus pre-drug control
doi:10.1371/journal.pone.0131432.t003
Fig 5. Effects of ranolazine on human right atrial action potentials. Action potentials were recorded in tissue from patients in SR (Aa) and in AF (Ba)
under control conditions and after exposure to increasing concentrations of ranolazine. Scale bar: from 0 to -80 mV in the y axis; 100 ms in the x axis.Ab-d
andBb-d: Ranolazine effects on (blue and purple), compared to spontaneous changes in time-matched control experiments (TMC) without any drug added
in plateau potential (mean potential at 20% of APD90 plus 5 ms, PLT20, Ab, Bb), on action potential duration at 90% of repolarization (APD90, Ac, Bc), and
maximum upstroke velocity (dV/dtmax, Ad, Bd). *P < 0.05; **P < 0.01; unpaired Student‘s t test.
doi:10.1371/journal.pone.0131432.g005
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plateau potential (PLT20) in AF trabeculae, and the effect of 100 μM ranolazine was significant
in both SR and AF preparations (Fig 5). The prolongation of APD90 in AF trabeculae (Table 3)
was not significant when compared to corresponding TMC values (Fig 5). With 100 μM rano-
lazine, dV/dtmax was considerably reduced, so that analysis and comparison of other parame-
ters was impossible because some preparations failed to respond to electrical stimulation.
Multicellular, superfused preparations usually require higher drug concentrations than single
cardiomyocytes because of non-homogeneous drug distribution within the tissue.
Expression of sodium channel subunits
Recently, cardiomyocytes were shown to express also other Na+ channel subunits in addition
to the cardiac specific Nav1.5 [28]. Therefore, the expression of various α- and β- subunits was
quantified by qPCR in 10 SR and 14 AF samples (Fig 6). As expected, the major pore-forming
α-subunit expressed in both SR and AF tissues was Nav1.5 (SCN5A). The TTX-sensitive chan-
nels SCN1A-4A were expressed at around 100-fold lower levels, which is in line with previous
published data on non-diseased human atria [28]. The neuronal Na+ channel isoform Nav1.6,
encoded by SCN8A, is upregulated in a rat model of heart failure and was suggested to contrib-
ute to INa,late [29]. This transcript was also expressed in human atrial tissue. The SCN10A tran-
script, encoding for Nav1.8, which was recently shown to be associated with slowing of
atrioventricular conduction [30,31], exhibited an expression level approximately 10.000-fold
lower than SCN5A. Though expressed at low levels only SCN2A, SCN8A and SCN10A showed
Fig 6. Expression of sodium channel subunits in right atrial tissue from patients in SR and AF.mRNA
expression of various Na+ channel alpha- (left) and beta- (right) subunits was quantified by qPCR in 10 and
14 samples of patients in SR and AF respectively. *p < 0.05; unpaired Student‘s t test.
doi:10.1371/journal.pone.0131432.g006
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significantly lower expression in AF than in SR. The SCN1B transcript encoding the Na+ chan-
nel β-subunit Navβ1 was expressed at high levels, SCN2B and SCN4B at intermediate levels
and SCN3B at fairly low levels, but expression of these transcripts did not differ between SR
and AF tissue.
Discussion
The main findings of our present study were: (i) confirmation of a very small INa,late as TTX-
sensitive current at room temperature, but not at physiological temperature, in human right
atrial cardiomyocytes with larger TTX-sensitive current in cells from AF than SR patients; (ii)
more prominent ranolazine effects on plateau potential and upstroke velocity in AF than SR
preparations, and (iii) lack of correlation between INa,late amplitude and expression of Nav1.x
α- and β-channel subunits in SR and AF tissue.
INa,late in ventricular and atrial cardiomyocytes from ΔKPQmice
One difficulty in detecting INa,late with standard rectangular clamp pulses is to discriminate
between “leak” currents and current flow through non-inactivating channels due to technical
limitations of the patch clamp technique. The seal resistance may not be sufficiently high to
minimize “leak” current unrelated to currents flowing through ion channels. These leak cur-
rents have a linear current-voltage relationship that crosses the abscissa at the junction poten-
tial. Assuming a typical seal resistance of ~1 GO, leak current at a test potential of -30 mV is
expected to be ~30 pA according to Ohm’s law. INa,late should become evident at the potential
of maximum Na+ channel activation, i.e. at ~-30 mV. However, in preliminary work with K+
currents minimized by substitution of Cs+ for K+ and L-type Ca2+ current blocked by exposing
the cells to 1 μM nisoldipine, we were not able to measure any additional persisting inward
conductance as a deviation from linearity [20]. This contrasted recently published findings by
Sossalla and coworkers [14] who reported ranolazine-sensitive INa,late for human atrial cardio-
myocytes with larger amplitude in AF than in SR, although it must be pointed out that statisti-
cal significance of the difference was reached only at 2 Hz and when estimating INa,late as area
under the curve by integrating the time-dependent current.
We have therefore checked the sensitivity of our set-up for detecting INa,late with ventricular
and atrial cardiomyocytes from ΔKPQ mice which clearly exhibit late Na+ current [8,22]. Our
protocol for human atrial cells (protocol I [20]) was directly compared with a slightly modified
protocol used by Sossalla et al. [14] (protocol II, see S1–S3 Figs). In addition, TTX (10 μM) was
used to identify current flow through Na+ channels. In ΔKPQ cardiomyocytes, TTX-sensitive
currents were verified in ventricular and atrial cells, however, current amplitudes were always
larger with protocol II than with protocol I. This result is expected, because at 40 mV more
negative holding potentials, i.e. -120 mV vs. -80 mV, more Na+ channels are available. Neither
protocol yielded evidence for INa,late in cardiomyocytes fromWTmice. These results indicate,
that INa,late is clearly detectable in our hands.
INa,late in human atrial cardiomyocytes
With TTX as a Na+ channel identifying tool INa,late could also be measured at room tempera-
ture with both protocols in human atrial cardiomyocytes, despite of a much smaller amplitude
than in murine ΔKPQmyocytes. TTX significantly reduced current at -30 mV in SR and AF
cells, and TTX-sensitive current was of significantly larger amplitude in AF than in SR cells.
Because of the small size of INa,late at 250 ms and the slow time course of its decay, current was
also analysed at 50 ms. Although this time interval is probably more relevant for the human
atrial AP, the technical limitations concerning escape from voltage control during activating
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INa,peak are more prominent. During loss of voltage control, Na
+ channel activation and subse-
quent inactivation is slower than at defined clamp potentials, and therefore, 50 ms may not be
enough time for regaining voltage control, whereas 250 ms is likely to be safe. Although quanti-
fication of INa,late becomes uncertain after escape it is noteworthy that there were significant
differences in TTX-sensitive late current between SR and AF.
Protocol II which had been designed by Sossalla et al. [14] to optimize voltage control by
activating reduced current amplitude close to the reversal potential of INa,peak at +50 mV before
stepping to the test pulse of -30 mV, could not be applied at 37°C because the cells did not tol-
erate a holding potential of -120 mV.
At physiological temperature TTX did not unmask any INa,late neither in SR nor in AF cells
after 250 ms. Here, TTX-sensitive current was significant when analysed after 50 ms and only
in AF. However, because of the even faster kinetics of INa,peak at 37°C, this finding could be an
artifact due to escape of voltage control.
Notwithstanding statistical significance, the absolute amplitudes of TTX-sensitive currents
at -30 mV were extremely small, ranging around or even below 10 pA. Average inward current
at -80 mV was about ten-fold larger (~90 pA in SR and ~130 pA in AF cells). Since TTX should
not affect current amplitude at -80 mV where Na+ channels are not active, cells in which cur-
rent shifted by>10 pA at -80 mV (or>20 pA at -120 mV when there was no pre-pulse to -80
mV) after addition of TTX were not accepted (see S4 –S6 Figs for comparison of results in
“selected” and “all data”). The major issue of this comparison is that, although TTX signifi-
cantly reduces current at -30 mV in all cells (S4 Fig), the statistical significance of the difference
between SR and AF cells is lost when cells with unstable holding current are included (see S5
Fig). In ΔKPQmice, comparison of “selected” versus “all” cardiomyocytes (S6 Fig) shows that
selection leads to an underestimation of TTX-sensitive current. The reason for this discrepancy
could be that ventricular cardiomyocytes from healthy mice have higher inward rectifier cur-
rent and are more stable in the first place, so that the selection criteria become arbitrary and
will worsen the outcome due to reduction in number.
Taken together, we have confirmed significant TTX-sensitive INa,late in human right atrial
cardiomyocytes at room temperature. This current was larger in cells from AF patients, sug-
gesting that remodeling during persistent AF enhances INa,late. Our study was not intended to
characterize the electrophysiological nature of INa,late.
Effect of ranolazine on human atrial tissue
Ranolazine (30 μM) significantly reduced current amplitude in AF, but was ineffective in SR
cells, irrespective of time of analysis. Action potentials from AF trabeculae were more sensitive
to ranolazine than APs from SR preparations, i.e. plateau potential PLT20 and maximum
upstroke velocity dV/dtmax were already reduced at 10-fold lower concentrations in AF than in
SR. In addition, AF, but not SR APs were significantly prolonged at all ranolazine
concentrations.
The ranolazine-sensitive current densities in AF myocytes after 50 ms and 250 ms of Na+
channel activation were ~0.14 pA/pF and ~0.09 pA/pF, respectively. The impact of this small
current on AF action potentials measured at physiological temperatures is difficult to estimate.
Although lowering of PLT20 is in accordance with hastening of the repolarization process
when persisting inward (depolarizing) current is blocked, this effect can equally well be
explained by inhibition of INa,peak as indicated by reduction of dV/dtmax which is a non-linear
surrogate parameter for Na+ channel availability, i.e. peak Na+ current [32,33]. In analogy to
the APD-shortening effect due to plateau potential elevation with IKur blockers [26], the pro-
longation of APD90 by ranolazine could be an indirect consequence of lowering of PLT20. In
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addition, block of hERG K+ channels by ranolazine [34] can contribute to APD lengthening.
Detailed selectivity analysis of ranolazine block of INa,late over various other ion currents is
available for dog ventricular and atrial cardiomyocytes [17,35], where the IC50 value for block
of INa,late (i.e. 5.9 μM) is in the range of therapeutic plasma concentrations (2–6 μM; [17]).
However, dog data cannot be directly interpolated to human tissue. We have recently reported
that plateau potential and APD90 were similarly altered in atrial cardiomyocytes from normal
SR and atrial-tachypaced dog hearts, and that dV/dtmax was in fact more sensitive to ranolazine
in SR than atrial tachypaced canine preparations [36].
Several recent reports suggest that patients with AF may benefit from treatment with rano-
lazine: Randomized controlled trials showed that treatment with ranolazine reduced the inci-
dence of new-onset AF [37], converted new-onset AF when used in a pill-in-the-pocket
approach [38] and was more effective than amiodarone in preventing post-operative AF [39].
These beneficial effects of ranoplazine have been attributed to atrial-selective block of INa,peak
and to block of IKr [19,35]. Like many other Na
+ channel blockers [40], ranolazine is consid-
ered to block preferentially INa,late over INa,peak, at least in ventricular cells [17]. Block of INa,peak
is an accepted antiarrhythmic mechanism for treatment of AF but is burdened with ventricular
proarrhythmic effects [41], therefore preferential block of INa,late has been suggested to be an
advantageous antiarrhythmic property for suppression of early and delayed afterdepolariza-
tions [19]. It should be noted that under the clinical conditions of the above-mentioned ran-
domized trials, atrial tissue is unlikely to have undergone substantial electrical remodelling, yet
in our experiments INa,late was inhibited by ranolazine only in remodelled cardiomyocytes from
patients with persistent AF, suggesting that the drug’s therapeutic effect in non-remodelled
atria may not be related to preferential block of INa,late. Other mechanisms of action such as
atrial-selective block of INa,peak due to a more negative potential of half-maximum inactivation
in atrial versus ventricular cells [35], frequency-dependent block of INa,peak and block of IKr, or
antioxidant properties are expected to contribute [16]. Although ranolazine inhibits INa,late
with higher potency than INa,peak, it is by no means selective for INa,late since several other ion
channels contributing to the shape of the atrial action potential are blocked as well [19].
Recently, Sicouri et al. reported about highly selective INa,late blocker GS-458967 [42], however,
this drug has not been available to us.
Expression of sodium channel subunits in SR and AF
Theoretically, a non-inactivating component of Na+ current could be related to a fraction of a
Na+ channel isoform with slow inactivation kinetics due to cellular modulation by for instance
phosphorylation [43], or, alternatively, due to different isoforms of the channel with distinct
kinetic properties [44]. We have detected, in addition to Nav1.5, β1 and β2, also substantial
expression of β4 and to a lower degree β3. Nav1.1.-Nav1.4 as well as Nav1.6 and Nav1.8 were
expressed at 100- to 1000-fold lower levels than Nav1.5, confirming that Nav1.5 proteins are
the major α-subunits of Na+ channels in human atria. Although the mRNA expression level of
the transcripts encoding Nav1.5 and all the β-subunits tended to be lower in AF than in SR, the
level of significance was not reached. Nav1.2, Nav 1.6, and Nav1.8, however, were expressed at
significantly lower levels in AF than SR tissue. The latter two channel isoforms have been asso-
ciated with late channel openings [45] contributing to INa,late in mouse and rabbit ventricular
cardiomyocytes [46] and were significantly lower expressed in AF than in SR. These expression
data render it unlikely that Nav1.6 and Nav1.8 subunits contribute to INa,late which was larger
in AF than in SR.
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Magnitude of INa,late
The contribution of INa,late to cellular Na
+ load is controversially discussed [15,47]. Most
authors agree that under normal conditions, more Na+ enters the cell via the Na,Ca exchanger
than via INa,late, but this relationship can change under pathophysiological conditions or at
rapid pacing rates [16,47,48]. Sossalla et al [14] reported a current-time integral of ~100 msA/
F, estimated over 200 ms. Assuming a mean cell capacitance ~100 pF, average current ampli-
tude during 200 ms would be 50 pA, but considerably smaller at the end of the 200 ms pulse
because inactivation continues. Assuming that INa,peak amounts to 10 nA, and assuming that
like in ventricular cardiomyocytes INa,late is less than 0.5–1% of INa,peak [44], the amplitude of
INa,late should be between 50 and 100 pA, indicating that INa,late is expected to be of a similar
order of magnitude as leak currents.
Though very small in amplitude when compared to INa,peak [44], INa,late cannot be neglected,
because persistent flow of even a small Na+ current during the plateau phase not only prolongs
action potential duration but also induces a Na+ load that may produce cellular Ca2+ overload.
Both long action potentials and Ca2+ overload are currently accepted mechanisms for arrhyth-
mogenesis in atrial fibrillation [15,49].
Conclusions
Our findings confirm and extend previously published data about the presence of INa,late in
human atria. Using TTX and ranolazine as tools to expose INa,late, we found in AF myocytes, an
average current density of approximately 0.15 pA/pF. This current may contribute to prolonga-
tion of early repolarization caused by AF-induced electrical remodelling (triangular AP shape
in AF vs. “spike-and-dome” morphology in SR). Our results must, however, be interpreted very
cautiously since the impact of such small current on human cardiac electrophysiology is
unclear. Furthermore, at physiological temperature the difference in INa,late amplitudes between
SR and AF cells did not reach the level of statistical significance. In conclusion, while this study
provides evidence for the presence of INa,late in human atria, the potential of such current as a
target for the treatment of AF remains to be demonstrated.
Supporting Information
S1 Fig. Effects of tetrodotoxin on INa,late measured at room temperature with protocol II in
ventricular and atrial cardiomyocytes from ΔKPQ-SCN5A mice. Same lay-out as in Fig 1.
(TIF)
S2 Fig. Original recordings of currents in human atrial myocytes. A and B: Examples of cur-
rents recorded with the complete protocol I (A) or protocol II (B) in human atrial myocytes
from patients in sinus rhythm (SR) or atrial fibrillation (AF).
(TIF)
S3 Fig. Effects of tetrodotoxin on INa,late measured with porotocol II in human atrial myo-
cytes at room temperature. A and B: Same lay-out as in Fig 2.
(TIF)
S4 Fig. Comparison of TTX effects on INa,late measured with protocol I and II in selected
cells (upper row) with results from all cells (lower row), analysis after 50 ms and 250 ms,
room temperature. P< 0.05; P< 0.01; P< 0.001; paired Student’s t-test (comparison
between control and drug effect).
(TIF)
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S5 Fig. Comparison of TTX-(10 μM)-sensitive current and ranolazine-(30 μM)-sensitive
current in selected cells (upper row) with results from all cells (lower row), analysis after 50
ms and 250 ms. INa,late in SR (black) and AF (red) was measured with protocol I and protocol
II for TTX, but only with protocol I for ranolazine. Currents are expressed in pA/pF. P< 0.05;
P< 0.01; P< 0.001; paired Student’s t-test (comparison between control and drug effect)
or unpaired Student‘s t test with Welch’s correction I (comparison between SR and AF).
(TIF)
S6 Fig. Comparison of tetrodotoxin- and ranolazine-sensitive currents in selected cells
(upper row) with results from all cells (lower row), analysis after 250 ms. Tetrodotoxin-
(10 μM)- and ranolazine-(30 μM)-sensitive currents in human atrial SR and AF cardiomyo-
cytes and tetrodotoxin-(10 μM)-sensitive currents in WT and ΔKPQmouse ventricular and
atrial myocytes measured with both protocols (protocol Ⅰ and Ⅱ) and analysed at -30 mV.
P< 0.05; P< 0.01; paired Student’s t-test (comparison between control and drug effect) or
unpaired Student‘s t test with Welch’s correction I (comparison between SR and AF). Numbers
below the columns (x/y) indicate number of cells per number of patients or animals.
(TIF)
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